Intelligence · Clinical Development
Pipeline search results
Programs matching “tislelizumab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 50 pipeline programs matching "tislelizumab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HNSCC
1 trial -
Tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Esophageal Squamous Cell Carcinoma (ESCC)
1 trial -
Tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
RECTAL NEOPLASMS
1 trial -
Tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Thyroid Cancer
1 trial -
Tislelizumab
Hospital Authority, Hong Kong
Pancreatic Neoplasms
1 trial -
Tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head and Neck Squamous Cell Carcinoma
1 trial -
Tislelizumab
BEONE MEDICINES AUS PTY LTD
Advanced Unresectable Gastric Adenocarcinoma
1 trial -
Tislelizumab
Takeda
Minimal Residual Disease
1 trial -
Tislelizumab
BeiGene
Cervical Cancer
1 trial -
Tislelizumab
BEONE MEDICINES AUS PTY LTD
Colorectal Cancer
1 trial -
Tislelizumab
The First People's Hospital of Lianyungang
Pancreatic Neoplasms
1 trial -
Tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Head and Neck Cancer
1 trial -
Tislelizumab
The First People's Hospital of Lianyungang
HER2-positive or Mutated Advanced Colorectal Cancer
1 trial -
Tislelizumab
BEONE MEDICINES AUS PTY LTD
Gastroesophageal Adenocarcinoma
1 trial -
Tislelizumab
The First People's Hospital of Lianyungang
Biliary Tract Tumor
1 trial -
Tislelizumab
BEONE MEDICINES AUS PTY LTD
Resectable Esophageal Squamous Cell Carcinoma
1 trial -
Tislelizumab
The First People's Hospital of Lianyungang
Bladder Urothelial Carcinoma
1 trial -
Tislelizumab (BGB-A317)
BEONE MEDICINES AUS PTY LTD
MSI-H/dMMR Solid Tumors
1 trial -
Tislelizumab combined with chemoradiotherapy
The First People's Hospital of Lianyungang
ESCC
1 trial -
Tislelizumab combined with chemotherapy
The First People's Hospital of Lianyungang
Rectal Cancer
1 trial -
combination with Disitamab Vedotin and with Tislelizumab and Capecitabine
Hospital Authority, Hong Kong
Gastric Cancer
1 trial -
tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric
1 trial -
tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Stage III
1 trial -
Tislelizumab
The First People's Hospital of Lianyungang
Advanced NSCLC
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.